Novartis halts phase 1 cancer trial of CD73 antagonist over efficacy, but combo studies continue

Novartis has halted a phase 1 trial of its CD73 antagonist due to a low likelihood of efficacy, although the Big Pharma will continue to explore the therapy’s potential as part of a combo regimen.